Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.

NCT00542308 is registered in ClinicalTrials.gov with Genmab as lead sponsor.

NCT NCT00542308
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00542308 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Single Arm Trial Investigating Zalutumumab, a Human Monoclonal Anti-EGF Receptor Antibody, in Combination With Best Supportive Care, in Patients With Non-Curable Squamous Cell Carcinoma of the Head and Neck Who Have Failed Standard Platinum-based Chemotherapy.
Lead sponsor
Genmab
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
August 31, 2011
Enrollment
90 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, squamous cell cancer